Committee for Medicinal Products for Human Use

Let's begin with an announcement from the European Medicines Agency, the EMA.

Their regulatory group that makes recommendations on drugs that should be approved is called the CHMP, and they announced this past week that the recommendation that the EMA authorize the marketing and clinical availability of secukinumab cosentix for the treatment of polymyalgia rheumatica.

This is based on the replenish trials and other data.

It's not yet approved in the European Union, but this is likely going to happen, and it's certainly not yet approved yet.

This approval underscores the burgeoning promise of personalized medicine, where treatments are meticulously tailored to individual genetic profiles, vastly improving patient outcomes.

Across the Atlantic, Europe's Committee for Medicinal Products for Human Use has given the nod to several new medicines, including notable contributions from Novo Nordisk and AstraZeneca.

Novo Nordisk's latest hemophilia treatment exemplifies its ongoing commitment to enhancing therapeutic solutions for blood disorders.

These CHMP endorsements are pivotal.

We can't label it an efficacy failure or a safety problem.

Turning to regulatory watch in Europe, Maat Pharma says CHMP confirmed its negative opinion on Zerviteg after re-examination.

The proposed microbiome therapy targets severe gut complications of acute graft versus host disease after transplantation.

Patients in the proposed indication have disease that's resisted treatment.

The negative opinion doesn't establish that the therapy has no benefit.

Next, EMA says its tailored clinical approach to biosimilars has produced its first positive recommendation.

CHMP backed Pbrilzo, a biosimilar to Roche's Perjeta for adult breast cancer.

Biosimilar collaborations.

Sanofi announced that the European Commission has approved an extension of the indication for MenQuadfi, meningococcal group C, W and Y conjugate vaccine, to include infants from six weeks of age to help protect against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y. MenQuadfi was previously approved in the EU for use in individuals aged 12 months and older.

The expanded indication follows the positive opinion adopted by the Committee for Medicinal Products for Human Use on June 25, 2026.

Roche Holding AG released new two-year data from the Phase 3b-4 Salween study of Vibasmo, presented at the 19th Asia-Pacific Vitreo-Retina Society Congress in Australia.

The results showed significant improvements in vision and retinal health in patients with polypoidal choroidal vasculopathy, a severe subtype of neovascular age-related macular degeneration, the leading cause of vision loss in people over the age of 60.